Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

Alpha 1-Antitrypsin Deficiency Clinical Trial

Official title:

The Effect of Augmentation Therapy With ARALAST Fraction IV-1 (ARALAST) Alpha1-Proteinase Inhibitor (α1-PI) on the Level of α1-PI and Other Analytes in the Bronchoalveolar (BAL) Epithelial Lining Fluid (ELF)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00396006
• Other study ID #: 460502
• Status: Completed
• Phase: Phase 4
• Start date: October 27, 2006
• Est. completion date: December 14, 2007

Study information

• Verified date: April 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects of weekly augmentation therapy with ARALAST Fraction IV-1 (Fr IV-1) on epithelial lining fluid (ELF) alpha 1-proteinase inhibitor levels and other ELF analytes and to assess the safety of the treatment. Eligible subjects with a diagnosis of severe congenital alpha 1-antitrypsin deficiency will receive 8 consecutive weekly treatments with 60 mg/kg/week of functional ARALAST Fr IV-1 administered intravenously. The efficacy and safety assessments will include two bronchoscopies with bronchoalveolar lavage on study initiation and on study termination and multiple imaging and laboratory safety assessments. Each subject will participate for a minimum of 12 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: December 14, 2007
• Est. primary completion date: December 14, 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed and dated informed consent.
• Male or female 18 years of age or older.
• Documented, endogenous serum a1-PI level < 40 mg/dL measured at screening (unless otherwise approved by the Sponsor) after a minimum of 28-day washout of any prior replacement therapy (if applicable).
• Phenotype Pi Z (which includes Pi*Z/Z, Pi*Z/Null, or Pi*Malton/Z), or Pi*Null/Null.
• Pulmonary functions at screening meeting the following criteria:

1. Forced expiratory volume at 1 second (FEV1) >= 50% of predicted value; or

2. FEV1 > 35% of predicted value and diffusing capacity for carbon monoxide > 45% of predicated value, with no supplemental oxygen therapy and < 3 pulmonary exacerbations or bronchitis requiring antibiotics/corticosteroids within the past 12 months).

• For any female of childbearing potential, a negative urine test for pregnancy within 7 days prior to the first bronchoalveolar lavage (BAL) visit and agreement to employ adequate birth control measures for the duration of the study.
• No clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG) performed at the screening visit (ECG previously obtained within the past 12 months may be used, if available).
• Laboratory results obtained at the screening visit, meeting the following criteria:

1. Serum alanine aminotransferase (ALT) <= 2 times upper limit of normal (ULN)

2. Serum aspartate aminotransferase (AST) <= 2 times ULN

3. Serum total bilirubin <= 2 times ULN

4. Proteinuria < +2 on dipstick analysis

5. Serum creatinine <= 1.5 times ULN

6. Absolute neutrophil count (ANC) >= 1500 cells/mm3

7. Hemoglobin (Hgb) >= 10.0 g/dL

8. Platelet count >= 105/mm3

• If the subject is treated with respiratory medications, such as inhaled bronchodilators or inhaled corticosteroids, or other chronic medications for the treatment of the subjects´s other medical condition(s), the subject's medication doses were unchanged for at least 14 days prior to the baseline BAL visit.

Exclusion Criteria:

• Clinically significant pulmonary impairment, other than chronic pulmonary disease (COPD).
• The subject has received any alpha 1 proteinase inhibitor (a1-PI) augmentation therapy (e.g., Prolastin, Zemaira, Aralast, or an investigational a1-PI, by any route including intravenous and inhaled) within 28 days prior to screening.
• The subject has received an investigational drug or device within 1 month prior to screening, or the subject is currently receiving an investigational drug or device. If the subject receives another investigational drug or device after enrollment, the subjects is to be withdrawn from the trial.
• Presence of clinical symptoms of any lower respiratory tract infection or acute pulmonary exacerbation within 14 days prior to screening.
• The subject has a known selective Immunoglobulin A (IgA) deficiency (IgA level less than 15 mg/dL) and/or antibody against IgA.
• The subject is pregnant or lactating, or intends to become pregnant during the course of the study.
• The subject is not a suitable candidate for a BAL procedure.
• Moderate or severe bronchiectasis (total daily sputum production > 10 mL).
• Clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance.
• Prior history of adverse reaction to local anaesthetics, sedatives, pain control drugs, and other medication employed at the study center for perioperative care associated with the BAL procedure.
• Long-term use of oral or parenteral glucocorticosteroid within 28 days prior to screening.

Related Conditions & MeSH terms

• Alpha 1-Antitrypsin Deficiency

Intervention

Biological:
• Alpha1-Proteinase Inhibitor
60 mg/kg, weekly, intravenous infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Baxalta now part of Shire

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in the BAL ELF Free Neutrophil Elastase Level	Median change in the BAL ELF Free Neutrophil Elastase Level from baseline to post-treatment	BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Other	Ratio of Post- to Pre-treatment BAL ELF Total Neutrophil Elastase Level	Median ratio of post- to pre-treatment BAL ELF Total Neutrophil Elastase Level	BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Other	Ratio of Post- to Pre-treatment BAL ELF Interleukin 8 (IL-8) Level	Median ratio of post- to pre-treatment BAL ELF IL-8 Level	BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Other	Change in the BAL ELF Tumor Necrosis Factor-alpha (TNF-a) From Baseline to Post-treatment	Median change in the BAL ELF TNF-a from baseline to post-treatment	BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Primary	Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (a1-PI) Level	Median change BAL ELF antigenic a1-PI level the from baseline to post-treatment	BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Primary	The Number of Adverse Events (AEs) Related to the Infusion of ARALAST Fr. IV 1 Administered at a Rate of 0.2 mL/kg/Min		During 8 consecutive weeks of treatment
Primary	Number of Changes in the Rate of Infusion	Number of decreases in the rate or discontinuations of infusion at 0.2 mL/kg/min	During 8 consecutive weeks of treatment
Secondary	Ratio of Post- to Pre-treatment BAL ELF Antineutrophil Elastase Capacity (ANEC) Levels	Median ratio of post- to pre-treatment BAL ELF ANEC levels	BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Secondary	Change in in the Ratio of BAL ELF a1-PI to Human Neutrophil Elastase (HNE) Complex Concentration	Median change in the ratio of BAL ELF a1-PI to HNE complex concentration from baseline to post-treatment	BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Secondary	Change in the a1-PI Plasma Level	Mean change in the plasma level of a1-PI from baseline to post-treatment	Blood samples were collected at baseline and after 8 consecutive weeks of treatment
Secondary	Change in the Plasma Antineutrophil Elastase Capacity (ANEC) Level	Mean change in the plasma ANEC level from baseline to post-treatment	Blood samples were collected at baseline and after 8 consecutive weeks of treatment
Secondary	Clinically Significant Changes in Vital Signs From Pre- to Post-Infusion	Clinically significant changes in vital signs from pre- to post-infusion are: • Heart rate: 25% increase above pre-infusion value • Blood pressure: = 30 mm Hg change from pre-infusion blood pressure (systolic or diastolic) • Temperature: an increase in body temperature to >38°C (>100.4°F). If the pre-infusion body temperature was already >38°C (>100.4°F), then any further increase in body temperature by 1.1°C (1.98°F) or more was considered clinically significant. • Respiratory rate: 25% increase above pre-infusion value	During 8 consecutive weeks of infusion